296
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the Turkish Bone Marrow Transplantation Study Group

, , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 1465-1474 | Received 06 Sep 2019, Accepted 06 Jan 2020, Published online: 08 Feb 2020
 

Abstract

We examined outcomes of 51 pediatric patients with relapsed acute leukemia (AL) who underwent a second allogeneic hematopoietic stem cell transplantation (alloHSCT). After a median follow-up of 941 days (range, 69–2842 days), leukemia-free survival (LFS) and overall survival (OS) at 3 years were 26.6% and 25.6%, respectively. The nonrelapse mortality rate (NMR) and cumulative incidence of relapse (CIR) were 36.4% and 42.4%, respectively. The Cox regression analysis demonstrated that the risk factors at second transplantation for predicting limited LFS were active disease (hazard ratio (HR) = 5.1), reduced intensity conditioning (RIC) (HR = 5.0), matched unrelated donor (MUD) (HR = 3.4) and performance score <80 (HR = 3.2). Pediatric patients with AL who relapsed after their first alloHSCT may survive with a second alloHSCT. Disease status, conditioning intensity, donor type, and performance score at the second transplantation are the relevant risk factors. A score based on these factors may predict the results of the second transplantation.

Acknowledgements

We acknowledge the support of American Journal Experts for English editing.

Author contributions

VH designed the study, collected and analyzed data, and wrote the paper; VU provided patient care and created the figures; GTK, NÖ, MK, GÖ, HD, SÇK, TA, EÜ, ÜK, AY, AA, OG, AK, FVO, Tİ, SK, İB, BŞK, MG, ZK, İOB, TP and SA provided patient care and contributed to the manuscript.

Disclosure statement

The authors declare no conflict of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.